<DOC>
	<DOCNO>NCT02632448</DOCNO>
	<brief_summary>The main purpose two-part study evaluate safety efficacy study drug know LY2880070 participant advance metastatic solid tumor .</brief_summary>
	<brief_title>A Study LY2880070 Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Have estimate life expectancy great equal ( â‰¥ ) 12 week Have adequate organ function Have receive 14 prior standard anticancer therapy Agree use medically approve contraceptive study 3 month follow last study treatment Females childbearing potential must negative serum pregnancy test result , negative urine pregnancy test result , prior first study treatment Have tumor lesion consider measurable Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 Must , judgment investigator , appropriate candidate experimental therapy , standard therapy would confer clinical benefit For Part A Must evidence cancer ( solid tumor , exclude glioblastoma primary brain tumor ) advance metastatic For Metabolism Phenotype Arm Part A , participant must Cytochrome P450 ( CYP2D6 ) poor metabolizer phenotype For Part B Have advance metastatic colorectal cancer , triple negative breast cancer ( per American Society Clinical OncologyCollege American Pathology guideline ) , epithelial ovarian cancer Participants ovarian cancer : Must eligible receive Gemcitabine ( GEM ) refractory GEM/carboplatin May receive GEM previous therapy circumstance , must complete last GEM regimen least 12 month prior study Have receive treatment investigational drug receive regulatory approval within 21 day first study treatment Have symptomatic central nervous system ( CNS ) metastasis Females pregnant nursing Have know positive test result human immunodeficiency virus , chronic active hepatitis A , B C Have correct QT interval ( QTcB ) great ( &gt; ) 470 millisecond ( msec ) ( female ) &gt; 450 msec ( male ) , history congenital long QT syndrome Have bone marrow transplant Have participate study , currently enrol another clinical study investigational medicinal product Have radiation therapy &gt; 25 % bone marrow For Part B Have history another active cancer within past year , except cervical cancer situ , situ carcinoma bladder , basal cell carcinoma skin , another situ carcinoma consider cure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic cancer</keyword>
	<keyword>Advanced cancer</keyword>
	<keyword>Recurrent cancer</keyword>
	<keyword>Colorectal neoplasm</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Ovarian neoplasm</keyword>
	<keyword>Colon neoplasm</keyword>
	<keyword>Rectal neoplasm</keyword>
	<keyword>Triple negative breast neoplasm</keyword>
</DOC>